Lawrence Kau

Company: Spark Therapeutics

Job title: Commercial Development

Bio:

Lawrence has spent the majority of his more than 20 years in the biotech industry working in rare genetic diseases and gene therapies. In his tenure at Spark Therapeutics, he has served in key cross-functional leadership roles in support of commercializing and launching LUXTURNA, the first ever gene therapy product for a genetic disease approved by the FDA, helping establish Spark as a pioneer in the commercialization of gene therapies. In his current role at Spark, as Global Commercial Strategy Lead, he leads cross-functional disease area commercialization strategy, and other high-level strategic initiatives involving commercial development of pipeline gene therapies for rare diseases. Lawrence earned his B.S. in Microbiology & Molecular Genetics from UCLA, and his M.B.A. in Marketing & Finance from The Wharton School.

Seminars:

Understanding what makes a gene therapy program commercially viable 10:40 am

Topics to be Discussed: Identifying viable target disease areas Maintaining a treatment-eligible patient pool through development and post-launch Discussing and brainstorming solutions for key limiting factors in the overall cost of commercializing a gene therapy Defining fair treatment pricesRead more

day: decision makers day - track b